Dendritic cells and gliomas: A hope in immunotherapy?;Cellules dendritiques et gliomes: Un espoir en immunothérapie?

Neurochirurgie

Volumn 52, Issue 6, 2006, Pages 555-570

  Jouanneau, E ^a,b   Poujol, D ^b   Caux, C ^b   Belin, M F ^a   Blay, J Y ^b   Puisieux, I ^b  

^a UNIVERSITÉ LYON 1   (France)

^b CENTRE LÉON BÉRARD   (France)

Author keywords

Clinical trials; Dendritic cells; Experimental studies; Glioma; Immunotherapy; Neuro oncology

Indexed keywords

ALPHA INTERFERON; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DENDRITIC CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 12; INTERLEUKIN 18; INTERLEUKIN 4; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN; TRANSFORMING GROWTH FACTOR BETA;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; B LYMPHOCYTE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CD8+ T LYMPHOCYTE; CLINICAL TRIAL; DENDRITIC CELL; FEASIBILITY STUDY; GLIOMA; HUMAN; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; PHENOTYPE; REVIEW; TUMOR RECURRENCE;

EID: 33845956661     PISSN: 00283770     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0028-3770(06)71367-4     Document Type: Review

References (70)

1. AKASAKI Y, KIKUCHI T, HOMMA S, ABE T, KOFE D, OHNO T. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J Immunother 2001 ; 24 : 106-113.
2. AOKI H, MIZUNO M, NATSUME A, TSUGAWA T, TSUJIMURA K, TAKAHASHI T, et al. Dendritic cells pulsed with tumor extract-cationic liposome complex increase the induction of cytotoxic T lymphocytes in mouse brain tumor. Cancer Immunol Immunother 2001 ; 50 : 463-468.
3. ASHLEY DM, FAIOLA B, NAIR S, HALE LP, BIGNER DD, GILBOA E. Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. J Exp Med 1997 ; 186 : 1177-1182.
4. BADIE B, SCHARTNER J, KLAVER J, VORPAHL J. In vitro modulation of microglia motility by glioma cells is mediated by hepatocyte growth factor/scatter factor. Neurosurgery 1999 ; 44 : 1077-1082.
5. BANCHEREAU J, PALUCKA AK, DHODAPKAR M, BURKEHOLDER S, TAQUET N, ROLLAND A, et al. Immune and clinical responses in patients with metastatic melanoma to CD34(+) progenitor-derived dendritic cell vaccine. Cancer Res 2001 ; 61 : 6451-6458.
6. BANCHEREAU J, SCHULER-THURNER B, PALUCKA AK, SCHULER G. Dendritic cells as vectors for therapy. Cell 2001 ; 106 : 271-274.
7. BARCHET W, BLASIUS A, CELLA M, COLONNA M. Plasmacytoid dendritic cells: in search of their niche in immune responses. Immunol Res 2005 ; 32 : 75-84.
8. CALZASCIA T, MASSON F, BERARDINO-B ESSON W, CONTASSOT E, WILMOTTE R, AURRAND-LIONS M, et al. Homing phenotypes of tumor-specific CD8 T cells are predetermined at the tumor site by crosspresenting APCs. Immunity 2005 ; 22 :175-184.
9. CANOVA, et al. Cancers et tumeurs dans cellules microgliales. Vol. 7. In : Neuroanatomie Fonctionnelle. Paris : Éditions ANPP.
10. CARREL S, DE TRIBOLET N, GROSS N. Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells. Eur J Immunol 1982 ; 12 : 354-357.
11. CARUSO DA, ORME LM, NEALE AM, RADCLIFF FJ, AMOR GM, MAIXNER W, et al. Results of a phase 1 study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children and young adults with brain cancer. Neuro-oncol 2004 ; 6 : 236-246.
12. CAUX C, DEZUTTER-DAMBUYANT C, SCHMITT D, BANCHEREAU J. GM-CSF and TNF-alpha cooperate in the generation of dendritic Langerhans cells. Nature 1992 ; 360 : 258-261.
13. DELHAYE M, CLAVREUL A, GARCION E, MENEI P. Vaccination contre les gliomes. Neurochirurgie 2003 ; 49 : 459-463.
14. DE TRIBOLET N, HAMOU MF, MACH JP, CARREL S, SCHREYER M. Demonstration of HLA-DR antigens in normal human brain. J Neurol Neurosurg Psychiatry 1984 ; 47 :417-418.
15. DE VLEESCHOUWER S, VAN CALENBERGH F, DEMAEREL P, FLAMEN P, RUTKOWSKI S, KAEMPGEN E, et al. Transient local response and persistent tumor control in a child with recurrent malignant glioma: treatment with combination therapy including dendritic cell therapy. Case report. J Neurosurg 2004 ; 100 :492-497.
16. DE VLEESCHOUWER S, ARREDOUANI M, ADE M, CADOT P, VERMASSEN E, CEUPPENS JL, et al. Uptake and presentation of malignant glioma tumor cell lysates by monocyte-derived dendritic cells. Cancer Immunol Immunother 2005 ; 54 : 372-382.
17. EHTESHAM M, KABOS P, GUTIERREZ MA, SAMOTO K, BLACK KL, YU JS. Intratumoral dendritic cell vaccination elicits potent tumoricidal immunity against malignant glioma in rats. J Immunother 2003 ; 26 : 107-116.
18. GABRILOVICH D, ISHIDA T, OYAMA T, RAN S, KRAVTSOV V, NADAF S, et al. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo. Blood 1998 ; 92 : 4150-4166.
19. GILBOA E. The makings of a tumor rejection antigen. Immunity 1999 ; 11 : 263-270.
20. GEHRMANN J, MATSUMOTO Y, KREUTZBERG GW. Microglia: intrinsic immune effector cell of the brain. Brain Res Brain Res Rev 1995 ; 20 : 269-287.
21. HEIMBERGER AB, CROTTY LE, ARCHER GE, MCLENDON RE, FRIEDMAN A, DRANOFF G, et al. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J Neuroimmunol 2000 ; 103 : 16-25.
22. INABA K, INABA M, ROMANI N, AYA H, DEGUCHI M, IKEHARA S, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor. J Exp Med 1992 ; 176 : 1693-1702.
23. INSUG O, KU G, ERTL HC, BLASZCZYK- THURIN M. A dendritic cell vaccine induces protective immunity to intracranial growth of glioma. Anticancer Res 2002 ; 22 : 613-621.
24. JONGMANS W, TIEMESSEN DM, VAN VLODROP IJ, MULDERS PF, OOSTERWIJK E. Th1-polarizing capacity of clinical-grade dendritic cells is triggered by Ribomunyl but is compromised by PGE2: the importance of maturation cocktails. J Immunother 2005 ; 28 : 480-487.
25. JONULEIT H, SCHMITT E. The regulatory T cell family: distinct subsets and their interrelations. J Immunol 2003 ; 171 : 6323-6327.
26. JOUANNEAU E, POUJOL D, GULIA S, LE MERCIER I, BLAY JY, BELIN MF, et al. Dendritic cells are essential for priming but inefficient for boosting antitumour immune response in an orthotopic murine glioma model. Cancer Immunol Immunother 2006 ; 55 : 254-267.
27. KALINSKI P, HILKENS CM, WIERENGA EA, KAPSENBERG ML. T-cell priming by type-1 and type-2 polarized dendritic cells: the concept of a third signal. Immunol Today 1999 ; 20 : 561-567.
28. KIKUCHI T, AKASAKI Y, IRIE M, HOMMA S, ABE T, OHNO T. Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol Immunother 2001 ; 50 : 337-344.
29. KIKUCHI T, ABE T, OHNO T. Effects of glioma cells on maturation of dendritic cells. J Neurooncol 2002 ; 58 : 125-130.
30. KIKUCHI T, AKASAKI Y, ABE T, OHNO T. Intratumoral injection of dendritic and irradiated glioma cells induces anti-tumor effects in a mouse brain tumor model. Cancer Immunol Immunother 2002 ; 51 : 424-430.
31. KIKUCHI T, AKASAKI Y, ABE T, FUKUDA T, SAOTOME H, RYAN JL, et al. Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12. J Immunother 2004 ; 27 : 452-459.
32. KJAERGAARD J, WANG LX, KURIYAMA H, SHU S, PLAUTZ GE. Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines. J Neurosurg 2005 ; 103 : 156-164.
33. KOBAYASHI T, YAMANAKA R, HOMMA J, TSUCHIYA N, YAJIMA N, YOSHIDA S, et al. Tumor mRNA-loaded dendritic cells elicit tumor-specific CD8(+) cytotoxic T cells in patients with malignant glioma. Cancer Immunol Immunother 2003 ; 52 : 632-637.
34. KUGLER A, STUHLER G, WALDEN P, ZOLLER G, ZOBYWALSKI A, BROSSART P, et al. Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids. Nat Med 2000 ; 6 : 332-336.
35. KUWASHIMA N, NISHIMURA F, EGUCHI J, SATO H, HATANO M, TSUGAWA T, et al. Delivery of dendritic cells engineered to secrete IFN-alpha into central nervous system tumors enhances the efficacy of peripheral tumor cell vaccines: dependence on apoptotic pathways. J Immunol 2005 ; 175 : 2730-2740.
36. LEE SC, LIU W, BROSNAN CF, DICKSON DW. GM-CSF promotes proliferation of human fetal and adult microglia in primary cultures. Glia 1994 ; 12 : 309-318.
37. LEUNG SY, WONG MP, CHUNG LP, CHAN AS, YUEN ST. Monocyte chemoattractant protein-1 expression and macrophage infiltration in gliomas. Acta Neuropathol 1997 ; 93 : 518-527.
38. LIAU LM, BLACK KL, PRINS RM, SYKES SN, DIPATRE PL, CLOUGHESY TF, et al. Treatment of intracranial gliomas with bone marrow-derived dendritic cells pulsed with tumor antigens. J Neurosurg 1999 ; 90 : 1115-1124.
39. LIAU LM, PRINS RM, KIERTSCHER SM, ODESA SK, KREMEN TJ, GIOVANNONE AJ, et al. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res 2005 ; 11 : 5515-5525.
40. MAC MENAMIN PG, FORRESTER JV. Dendritic cells in the central nervous system and eye and their associated supporting tissues. In: Dendritic cells: biology and clinical applications. New York: Academic Press, 1999.
41. MALDONADO-LOPEZ R, MOSER M. Dendritic cell subsets and the regulation of Th1/Th2 responses. Semin Immunol 2001 ; 13 : 275-282.
42. MELLMAN I, STEINMAN RM. Dendritic cells: specialized and regulated antigen processing machines. Cell 2001 ; 106 : 255-258.
43. MENETRIER-CAUX C, MONTMAIN G, DIEU MC, BAIN C, FAVROT MC, CAUX C, et al. Inhibition of the differentiation of dendritic cells from CD34(+) progenitors by tumor cells: role of interleukin-6 and macrophage colony-stimulating factor. Blood 1998 ; 92 : 4778-4791.
44. NESTLE FO, ALIJAGIC S, GILLIET M, SUN Y, GRABBE S, DUMMER R, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med 1998 ; 4 : 328-332.
45. NI HT, SPELLMAN SR, JEAN WC, HALL WA, LOW WC. Immunization with dendritic cells pulsed with tumor extract increases survival of mice bearing intracranial gliomas. J Neurooncol 2001 ; 51 : 1-9.
46. O'NEILL DW, ADAMS S, BHARDWAJ N. Manipulating dendritic cell biology for the active immunotherapy of cancer. Blood 2004 ; 104 : 2235-2246.
47. PARNEY IF, HAO C, PETRUK KC. Glioma immunology and immunotherapy. Neurosurgery 2000 ; 46 : 778-791.
48. PHAN GQ, YANG JC, SHERRY RM, HWU P, TOPALIAN SL, SCHWARTZENTRUBER DJ, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA 2003 ; 100 : 8372-8377.
49. PRINS RM, ODESA SK, LIAU LM. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Cancer Res 2003 ; 63 : 8487-8491.
50. RUTKOWSKI S, DE VLEESCHOUWER S, KAEMPGEN E, WOLFF JE, KUHL J, DEMAEREL P, et al. Surgery and adjuvant dendritic cell-based tumour vaccination for patients with relapsed malignant glioma, a feasibility study. Br J Cancer 2004 ; 91 : 1656-1662.
51. SAITO R, MIZUNO M, NAKAHARA N, TSUNO T, KUMABE T, YOSHIMOTO T, et al. Vaccination with tumor cell lysate-pulsed dendritic cells augments the effect of IFN-beta gene therapy for malignant glioma in an experimental mouse intracranial glioma. Int J Cancer 2004 ; 111 : 777-782.
52. SANTAMBROGIO L, BELYANSKAYA SL, FISCHER FR, CIPRIANI B, BROSNAN CF, RICCIARDI-CASTAGNOLI P, et al. Developmental plasticity of CNS microglia. Proc Natl Acad Sci USA 2001 ; 98 : 6295-6300.
53. SPARANO JA, GRAY R, GIANTONIO B, O'DWYER P, COMIS RL. Evaluating antiangiogenesis agents in the clinic: the Eastern Cooperative Oncology Group Portfolio of Clinical Trials. Clin Cancer Res 2004 ; 10 : 1206-1211.
54. STEINMAN RM. The dendritic cell system and its role in immunogenicity. Annu Rev Immunol 1991 ; 9 : 271-296.
55. STEINMAN RM, HAWIGER D, NUSSENZWEIG MC. Tolerogenic dendritic cells. Annu Rev Immunol 2003 ; 21 : 685-711.
56. SUZUMURA A, SILBERBERG DH. MHC antigen expression on glial cells. Ann NY Acad Sci 1988 ; 540 : 495-497.
57. TSUGAWA T, KUWASHIMA N, SATO H, FELLOWS-MAYLE WK, DUSAK JE, OKADA K, et al. Sequential delivery of interferon-alpha gene and DCs to intracranial gliomas promotes an effective antitumor response. Gene Ther 2004 ; 11 : 1551-1558.
58. VICARI AP, CAUX C, TRINCHIERI G. Tumour escape from immune surveillance through dendritic cell inactivation. Semin Cancer Biol 2002 ; 12 : 33-42.
59. WALKER PR, CALZASCIA T, DE TRIBOLET N, DIETRICH PY. T-cell immune responses in the brain and their relevance for cerebral malignancies. Brain Res Brain Res Rev 2003 ; 42 : 97-122.
60. WALLENFRIEDMAN MA, CONRAD JA, DELAB ARRE L, GRAUPMAN PC, LEE G, GARWOOD M, et al. Effects of continuous localized infusion of granulocyte-macrophage colony-stimulating factor and inoculations of irradiated glioma cells on tumor regression. J Neurosurg 1999 ; 90 : 1064-1071.
61. YAMANAKA R, ZULLO SA, TANAKA R, BLAESE M, XANTHOPOULOS KG. Enhancement of antitumor immune response in glioma models in mice by genetically modified dendritic cells pulsed with Semliki forest virus-mediated complementary DNA. J Neurosurg 2001 ; 94 : 474-481.
62. YAMANAKA R, YAJIMA N, TSUCHIYA N, HONMA J, TANAKA R, RAMSEY J, et al. Administration of interleukin-12 and -18 enhancing the antitumor immunity of genetically modified dendritic cells that had been pulsed with Semliki forest virus-mediated tumor complementary DNA. J Neurosurg 2002 ; 97 : 1184-1190.
63. YAMANAKA R, ZULLO SA, RAMSEY J, YAJIMA N, TSUCHIYA N, TANAKA R, et al. Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12. J Neurosurg 2002 ; 97 : 611-618.
64. YAMANAKA R, TSUCHIYA N, YAJIMA N, HONMA J, HASEGAWA H, TANAKA R, et al. Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12. J Neurosurg 2003 ; 99 : 746-753.
65. YAMANAKA R, ABE T, YAJIMA N, TSUCHIYA N, HOMMA J, KOBAYASHI T, et al. Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial. Br J Cancer 2003 ; 89 : 1172-1179.
66. YAMANAKA R, HOMMA J, YAJIMA N, TSUCHIYA N, SANO M, KOBAYASHI T, et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial. Clin Cancer Res 2005 ; 11 : 4160-4167.
67. YOSHIDA S, MORII K, WATANABE M, SAITO T, YAMAMOTO K, TANAKA R. The generation of anti-tumoral cells using dentritic cells from the peripheral bloood of patients with malignant brain tumors. Cancer Immunol Immunother 2001 ; 50 : 321-327.
68. YU JS, WHEELER CJ, ZELTZER PM, YING H, FINGER DN, LEE PK, et al. Vaccination of malignant glioma patients with peptide-pulsed dendritic cells elicits systemic cytotoxicity and intracranial T-cell infiltration. Cancer Res 2001 ; 61 : 842-847.
69. YU JS, LIU G, YING H, YONG WH, BLACK KL, WHEELER CJ. Vaccination with tumor lysate-pulsed dendritic cells elicits antigen-specific, cytotoxic T-cells in patients with malignant glioma. Cancer Res 2004 ; 64 : 4973-4979.
70. ZHU X, LU C, XIAO B, QIAO J, SUN Y. An experimental study of dendritic cells-mediated immunotherapy against intracranial gliomas in rats. J Neurooncol 2005 ; 74 : 9-17.